Releuko is paid 69.0% below Neupogen
4 biosimilars bill against Neupogen (J1442). On average they are paid ↓ 49.7% relative to the reference product per 1 MCG in 4Q26.
- Neupogen (reference)
- Releuko
- Nivestym
- Zarxio
- Nypozi
AfliberceptBevacizumabDenosumabEculizumabEpoetin alfaFilgrastimInfliximabNatalizumabPegfilgrastimRanibizumabRituximabTocilizumabTrastuzumabUstekinumab
All products
| Product | Code | CMS description | Per 1 MCG | vs. reference | CMS 8% add-on note | 8 quarters |
|---|---|---|---|---|---|---|
| Neupogen | J1442 | Inj filgrastim excl biosimil | $0.994 | Reference | – | |
| Releuko | Q5125 | Inj, releuko 1 mcg | $0.308 | ↓ 69.0% | Yes | |
| Nivestym | Q5110 | Nivestym | $0.329 | ↓ 66.9% | Yes | |
| Zarxio | Q5101 | Injection, zarxio | $0.338 | ↓ 66.0% | Yes | |
| Nypozi | Q5148 | Inj, nyposi 1 mcg | $1.026 | ↑ 3.2% | No |
Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.